In lung cancer, MET mutations are rare, but amplification is seen in up to 21%, resulting in constitutive MET activation and is believed to be a potential mechanism of acquired EGFR TKI resistance (28, 29). The gene discussed is EGFR; the disease is lung carcinoma.